Home  |  Contact

UniProtKB/Swiss-Prot P38398: Variant p.Asp749Tyr

Breast cancer type 1 susceptibility protein
Gene: BRCA1
Feedback?
Variant information Variant position: help 749 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Aspartate (D) to Tyrosine (Y) at position 749 (D749Y, p.Asp749Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to large size and aromatic (Y) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In BC. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 749 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1863 The length of the canonical sequence.
Location on the sequence: help EEKEEKLETVKVSNNAEDPK D LMLSGERVLQTERSVESSSI The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         EEKEEKLETVKVSNNAEDPKDLMLSGERVLQ-TERSVESSSI

Gorilla                       EEKEEKLETVKVSNNAEDPKDLMLSGERVLQ-TERSVESSS

Rhesus macaque                EEKEEKLETVKVSNNAKDPKDLMLSGERVLQ-TERSVESSS

Chimpanzee                    EEKEEKLETVKVSNNAEDPKDLMLSGERVLQ-TERSVESSS

Mouse                         RTGTEQLETRQMSDSAKELGDRVLGGEPSGKTTDRSEESTS

Rat                           RKGIEQLEMCQMPDNNKELGDLVLGGEPSGKPTEPSEESTS

Bovine                        E---ENLGTIQVSNSTKDPKDLILREGKALQ-IERSVESTN

Caenorhabditis elegans        -----------ATKQPVELQSRVFPLEKLKKDVETSTETYK
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1863 Breast cancer type 1 susceptibility protein
Modified residue 753 – 753 Phosphoserine
Cross 734 – 734 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)
Cross 739 – 739 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)
Alternative sequence 64 – 1863 Missing. In isoform 2.
Alternative sequence 224 – 1365 Missing. In isoform 5.
Alternative sequence 264 – 1366 Missing. In isoform 3 and isoform 6.



Literature citations
BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico.
Ruiz-Flores P.; Sinilnikova O.M.; Badzioch M.; Calderon-Garciduenas A.L.; Chopin S.; Fabrice O.; Gonzalez-Guerrero J.F.; Szabo C.; Lenoir G.; Goldgar D.E.; Barrera-Saldana H.A.;
Hum. Mutat. 20:474-475(2002)
Cited for: VARIANT BC TYR-749;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.